Business Insider25d
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
ANB032 was well tolerated across all doses with no safety signals observed AD trial and all further investment in ANB032 will be discontinued Anticipate top-line Phase 2b data in rheumatoid ...
Yahoo Finance24d
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
ANB032 was well tolerated with no safety signals observed. “While ANB032 was safe and well tolerated, we’re disappointed by these efficacy results in AD and will discontinue further investment ...
Morningstar25d
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
Morningstar brands and products Company Portfolio ...
Business Insider25d
AnaptysBio announces Phase 2b trial of ANB032 did not meet primary endpoint
AnaptysBio (ANAB) announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the global, 201-patient ARISE-AD trial as a ...
Taiwan News25d
Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
ANB032 was well tolerated across all doses with no safety signals observed AD trial and all further investment in ANB032 will be discontinued Anticipate top-line Phase 2b data in rheumatoid arthritis ...
Nasdaq25d
AnaptysBio's Shares Plunge As Phase 2b Study Of ANB032 In Atopic Dermatitis Fails
(RTTNews) - Shares of AnaptysBio, Inc. (ANAB) are down over 30% as the clinical-stage biotechnology company announced that its Phase 2b trial of ANB032 in Atopic Dermatitis did not meet the ...